Healthy Volunteers
Conditions
Brief summary
The purpose of this study is to evaluate the safety and tolerability, and determine the blood levels (pharmacokinetics), in both a fed and fasted condition, of a single dose of ASN002. Healthy volunteers will be participants in the study.
Interventions
DRUGASN002
Single dose study with food effect
Sponsors
Asana BioSciences
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male or female, non-smoking subjects. 2. Willing to use contraception throughout the duration of the study and for 90 days after the study. 3. Capable of consent.
Exclusion criteria
Subjects to whom any of the following applies will be excluded from the study: 1. Any clinically significant abnormality, infection, exposure to infection, recent live virus vaccination, or abnormal laboratory test results found during medical screening. 2. History of alcohol or drug abuse, or a positive urine drug screen or breath alcohol test at screening. 3. History of allergic reactions to protein kinase inhibitors, or significant allergic reactions to any drug. 4. Positive pregnancy test at screening. 5. Clinically significant ECG abnormalities. 6. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration. 7. Use of medication other than topical products without significant systemic absorption: 8. Donation of plasma within 7 days prior to dosing, or significant blood loss within the past 56 days. 9. Subject is pregnant, or breast feeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects reporting adverse events during the study | Days 1-28 | Safety and tolerability will be determined by the number of subjects reporting adverse events during the study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the plasma concentration versus time curve (AUC) under fed and fasted conditions | Days 1-6 | Calculate Area under the plasma concentration time curve (AUC) from time 0 to infinity after first dose. AUC from time 0 to the time of last measured concentration. AUC from time 0 to 24 hours. |
| Maximum Plasma Concentration of ASN002 | Days 1-6 | Calculate observed maximum plasma concentration after a dose and observed maximum plasma concentration at steady state. The time to reach the peak plasma concentration. The time to reach the peak plasma concentration at steady state. |
| Area under the plasma concentration versus time curve (AUC) | Days 1-6 | Calculate Area under the plasma concentration time curve (AUC) from time 0 to infinity after first dose. AUC from time 0 to the time of last measured concentration. AUC from time 0 to 24 hours. |
| Drug half life of ASN002 | Days 1-6 | Calculate terminal elimination rate constant and terminal half-life of ASN002 |
| Drug half life of ASN002 under fed and fasted conditions | Days 1-6 | Calculate terminal elimination rate constant and terminal half-life of ASN002 |
| Maximum Plasma Concentration of ASN002 under fed and fasted conditions | Days 1-6 | Calculate observed maximum plasma concentration after a dose and observed maximum plasma concentration at steady state. The time to reach the peak plasma concentration. The time to reach the peak plasma concentration at steady state. |
Countries
United States
Outcome results
None listed